Local Treatment for Relapsing Glioblastoma: A Decision-making Tree for Choosing Between Reirradiation and Second Surgery
Overview
Authors
Affiliations
In case of circumscribed recurrent glioblastoma (rec-GBM), a second surgery (Re-S) and reirradiation (Re-RT) are local strategies to consider. The aim is to provide an algorithm to use in the daily clinical practice. The first step is to consider the life expectancy in order to establish whether the patient should be a candidate for active treatment. In case of a relatively good life expectancy (>3 months) and a confirmed circumscribed disease(i.e. without multiple lesions that are in different lobes/hemispheres), the next step is the assessment of the prognostic factors for local treatments. Based on the existing prognostic score systems, patients who should be excluded from local treatments may be identified; based on the validated prognostic factors, one or the other local treatment may be preferred. The last point is the estimation of expected toxicity, considering patient-related, tumor-related and treatment-related factors impacting on side effects. Lastly, patients with very good prognostic factors may be considered for receiving a combined treatment.
Non-neoplastic astrocytes: key players for brain tumor progression.
Catalano M, Limatola C, Trettel F Front Cell Neurosci. 2024; 17:1352130.
PMID: 38293652 PMC: 10825036. DOI: 10.3389/fncel.2023.1352130.
Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects.
Pineda E, Domenech M, Hernandez A, Comas S, Balana C Onco Targets Ther. 2023; 16:71-86.
PMID: 36721854 PMC: 9884437. DOI: 10.2147/OTT.S366371.
Glioblastoma - treatment and obstacles.
Cantidio F, Gil G, Queiroz I, Regalin M Rep Pract Oncol Radiother. 2022; 27(4):744-753.
PMID: 36196416 PMC: 9521695. DOI: 10.5603/RPOR.a2022.0076.
Granata V, Ianniello S, Fusco R, Urraro F, Pupo D, Magliocchetti S J Pers Med. 2021; 11(11).
PMID: 34834455 PMC: 8623042. DOI: 10.3390/jpm11111103.
Re-irradiation for high-grade gliomas: Has anything changed?.
Garcia-Cabezas S, Rivin Del Campo E, Solivera-Vela J, Palacios-Eito A World J Clin Oncol. 2021; 12(9):767-786.
PMID: 34631441 PMC: 8479348. DOI: 10.5306/wjco.v12.i9.767.